Table 2.
Achieving fixed targets: the annual number of susceptible PWID who must be vaccinated for every reduction in treatments administered in order to maintain a specified reduction in prevalence
| 75 % relative prevalence reduction target | 50 % relative prevalence reduction target | 25 % relative prevalence reduction target | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Time to target (years) | 10 | 15 | 30 | 10 | 15 | 30 | 10 | 15 | 30 | |
| 25 % initial chronic HCV prevalence among PWID | ||||||||||
| Vaccine efficacy | 90 % | 17.7 | 13.9 | 8.5 | 14.1 | 10.4 | 6.7 | 11.2 | 8.0 | 5.6 |
| 60 % | 26.8 | 21.3 | 14.1 | 21.2 | 15.5 | 10.0 | 17.0 | 12.1 | 8.5 | |
| 30 % | 60.9 | 41.6 | 38.1 | 41.9 | 30.8 | 20.0 | 34.9 | 24.6 | 16.9 | |
| 50 % initial chronic HCV prevalence among PWID | ||||||||||
| 90 % | 5.8 | 4.3 | 2.9 | 4.3 | 3.2 | 2.1 | 3.4 | 2.4 | 1.6 | |
| 60 % | 8.6 | 6.3 | 4.3 | 6.5 | 4.8 | 3.2 | 5.1 | 3.7 | 2.4 | |
| 30 % | 17.2 | 13.0 | 8.9 | 13.0 | 9.7 | 6.5 | 10.3 | 7.5 | 4.9 | |
| 75 % initial chronic HCV prevalence among PWID | ||||||||||
| 90 % | 2.0 | 1.4 | 1.0 | 1.4 | 1.0 | 0.7 | 1.1 | 0.8 | 0.5 | |
| 60 % | 3.0 | 2.1 | 1.5 | 2.2 | 1.5 | 1.0 | 1.6 | 1.1 | 0.8 | |
| 30 % | 5.6 | 4.3 | 2.9 | 4.3 | 3.1 | 2.1 | 3.2 | 2.3 | 1.5 | |
HCV hepatitis C virus, PWID people who inject drugs